EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diffusion MRI is superior to quantitative T2-FLAIR mismatch in predicting molecular subtypes of human non-enhancing gliomas

Nicholas S Cho, Francesco Sanvito, Viên Lam Le, Sonoko Oshima, Ashley Teraishi, Jingwen Yao, Donatello Telesca, Catalina Raymond, Whitney B Pope, Phioanh L Nghiemphu, Albert Lai, Noriko Salamon und 2 weitere

Neuroradiology · 2024

DOI: 10.1007/s00234-024-03475-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroradiology, 2024. Verfasst von Nicholas S Cho und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Diffusion Magnetic Resonance Imaging. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study compared the classification performance of normalized apparent diffusion coefficient (nADC) with percentage T2-FLAIR mismatch-volume (%T2FM-volume) for differentiating between IDH-mutant astrocytoma (IDHm-A) and other glioma molecular subtypes.

Methods

A total of 105 non-enhancing gliomas were studied. T2-FLAIR digital subtraction maps were used to identify T2FM and T2-FLAIR non-mismatch (T2FNM) subregions within tumor volumes of interest (VOIs). Median nADC from the whole tumor, T2FM, and T2NFM subregions and %T2FM-volume were obtained. IDHm-A classification analyses using receiver-operating characteristic curves and multiple logistic regression were performed in addition to exploratory survival analyses.

Results

T2FM subregions had significantly higher nADC than T2FNM subregions within IDHm-A with ≥ 25% T2FM-volume ( P < 0.0001). IDHm-A with ≥ 25% T2FM-volume demonstrated significantly higher whole tumor nADC compared to IDHm-A with < 25% T2FM-volume ( P < 0.0001), and both IDHm-A subgroups demonstrated significantly higher nADC compared to IDH-mutant oligodendroglioma and IDH-wild-type gliomas ( P < 0.05). For classification of IDHm-A vs. other gliomas, the area under curve (AUC) of nADC was significantly greater compared to the AUC of %T2FM-volume ( P = 0.01, nADC AUC = 0.848, %T2FM-volume AUC = 0.714) along with greater sensitivity. In exploratory survival analyses within IDHm-A, %T2FM-volume was not associated with overall survival ( P = 0.2), but there were non-significant trends for nADC ( P = 0.07) and tumor volume ( P = 0.051).

Conclusion

T2-FLAIR subtraction maps are useful for characterizing IDHm-A imaging characteristics. nADC outperforms %T2FM-volume for classifying IDHm-A amongst non-enhancing gliomas with preserved high specificity and increased sensitivity, which may be related to inherent diffusivity differences regardless of T2FM. In line with previous findings on visual T2FM-sign, quantitative %T2FM-volume may not be prognostic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsDiffusion Magnetic Resonance ImagingHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedTumor BurdenSensitivity and SpecificityImage Interpretation, Computer-AssistedMutationPredictive Value of TestsIsocitrate Dehydrogenase

Stichwörter der Autor:innen

Diffusion MRIDigital subtractionIDH-mutant gliomaMRIT2-FLAIR mismatch sign

Substanzen

Isocitrate Dehydrogenase

Autor:innen und Institutionen

  • Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA.
  • Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, CA, USA.
  • Medical Scientist Training Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA.
  • UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

Förderung

  • NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • U.S. Department of Defense
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Cho, N. S., Sanvito, F., Le, V. L., Oshima, S., Teraishi, A., Yao, J., Telesca, D., Raymond, C., Pope, W. B., Nghiemphu, P. L., Lai, A., Salamon, N., Cloughesy, T. F., & Ellingson, B. M. (2024). Diffusion MRI is superior to quantitative T2-FLAIR mismatch in predicting molecular subtypes of human non-enhancing gliomas. Neuroradiology. https://doi.org/10.1007/s00234-024-03475-z

Vancouver

Cho NS, Sanvito F, Le VL, Oshima S, Teraishi A, Yao J, et al. Diffusion MRI is superior to quantitative T2-FLAIR mismatch in predicting molecular subtypes of human non-enhancing gliomas. Neuroradiology. 2024. doi:10.1007/s00234-024-03475-z

BibTeX
@article{Cho2024,
  author = {Cho, Nicholas S and Sanvito, Francesco and Le, Viên Lam and Oshima, Sonoko and Teraishi, Ashley and Yao, Jingwen and Telesca, Donatello and Raymond, Catalina and Pope, Whitney B and Nghiemphu, Phioanh L and Lai, Albert and Salamon, Noriko and Cloughesy, Timothy F and Ellingson, Benjamin M},
  title = {Diffusion MRI is superior to quantitative T2-FLAIR mismatch in predicting molecular subtypes of human non-enhancing gliomas},
  journal = {Neuroradiology},
  year = {2024},
  doi = {10.1007/s00234-024-03475-z}
}
Kostenlos starten →